history& perspectives

A Medtech start-up

An authentic breakthrough innovation

In 2005, a team led by Valerie Weaver (Berkeley) passed in vitro human breast cells from the normal state to the cancerous state and vice versa by playing on the pressure of the environment. This experience, confirmed since by many others, is a revolution in the understanding of cancer, at the same time it opens up prospects of unexpected therapy.

To our knowledge, we are the first company in the world to translate these results into an applied therapeutic solution in vivo.

The main part of our efforts is to imagine, manufacture and test devices for exerting a field of constraint on a tumor.

A capitalized development

Like any independent start-up involving real innovation, we rely on capital increases to finance our research.

On the road to Proof of Efficacy

After the publication of our Proof of Concept (PlosOne 2016) and the validation of our research axes by the scientific community, we can begin in 2017 the realization of our Proof of Efficacy, that is to say the transplant of human pancreatic cancer grafted in the pancreas of mice, which will then be treated by our technology, the objective being to prove that the treatment allows at least the control of the tumoral growth until the reduction of the size of the grafted tumor – and at best to obtain the restitution of the normal architecture of the pancreatic tissue, that is, healing.

Learn more about our Proof of Efficacy…

Two consortia were set up in 2017:

– In the United States, the partnership with the Laboratory of Physical Oncology at Stanford University has been formalized. We are very excited about this collaboration. On the one hand, it immerses us in the heart of the very rich Medtech ecosystem of the San Francisco area, with the support of one of the most powerful universities in the world. On the other hand, it is a first step towards US investors – and ultimately towards the US market.

Learn more about the partnership with Stanford University …

– In Europe, a consortium has been set up with teams from Bichat Hospital in Paris, one of the world leaders in Digestive Oncology. This large-scale experiment will allow us not only to obtain our Proof of Efficacy, but also to begin to test the feasibility for the Human Prototype, and to explore the response of other cancerous lineages (glioblastoma, hepatic adenocarcinoma).

In parallel, we are also working on the drafting of specifications for the realization of the human prototype. It should be noted that field gradient generator prototypes for humans have already been developed and tested in MPI (Magnetic Particle Imagery), in particular by Philips and Bruker. That is reassuring news about the technical feasibility and toxicity of our device.

governance

The team

Barthélémy Brossel
CEO

In charge of administration and communication.

Rémy Brossel
CSO

Medical oncologist and physicist, he ensures the interface between the various scientific partners, subcontractors and opinion leaders.

Christine Grau
Executive Assistant

Founded in 2009 by members of the Brossel family, CC & C is a Société Anonyme (SA) with a capital of 395.075 € with 87 shareholders (march 2018). The patent belongs to the company.

The Scientific Board

Daniel Gabay
Mathematician (Polytechnique, PhD)

Retired Director of Research in Mathematics at CNRS

Stéphane David
Industrial Manager (PhD, CEA)
Specialist in electro-magnetism

Christian Chillet
Researcher (PhD, CNRS / G2E Lab)

Specialist in electro-magnetism

Jean-Marc Guinebretière
MD (Institut Curie)

Pathologist

Eric Peltier
MD, CEO of Novacyt

Specialist in the development of medical devices

Roy Wiener
Medical Oncologist (Retired Dean Ass, Tulane Uni., US-LA)

A bridge to American healthcare institutions

partners

Adapted and flexible ecosystem

We have chosen to work in a network to add, on a case by case basis and according to needs, the skills we need.

For electro-technical engineering :

For research and experimentation :

Institutional partners:

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles

history& perspectives

A Medtech start-up

An authentic breakthrough innovation

In 2005, a team led by Valerie Weaver (Berkeley) passed in vitro human breast cells from the normal state to the cancerous state and vice versa by playing on the pressure of the environment. This experience, confirmed since by many others, is a revolution in the understanding of cancer,at the same time it opens up prospects of unexpected therapy.

To our knowledge, we are the first company in the world to translate these results into an applied therapeutic solution in vivo.

The main part of our efforts is to imagine, manufacture and test devices for exerting a field of constraint on a tumor.

A capitalized development

Like any independent start-up involving real innovation, we rely on capital increases to finance our research.

On the road to Proof of Efficacy

After the publication of our Proof of Concept (PlosOne 2016) and the validation of our research axes by the scientific community, we can begin in 2017 the realization of our Proof of Efficacy, that is to say the transplant of human pancreatic cancer grafted in the pancreas of mice, which will then be treated by our technology, the objective being to prove that the treatment allows at least the control of the tumoral growth until the reduction of the size of the grafted tumor – and at best to obtain the restitution of the normal architecture of the pancreatic tissue, that is, healing.

Learn more about our Proof of Efficacy…

Two consortia were set up in 2017:

– In the United States, the partnership with the Laboratory of Physical Oncology at Stanford University has been formalized. We are very excited about this collaboration. On the one hand, it immerses us in the heart of the very rich Medtech ecosystem of the San Francisco area, with the support of one of the most powerful universities in the world. On the other hand, it is a first step towards US investors – and ultimately towards the US market.

Learn more about the partnership with Stanford University …

– In Europe, a consortium has been set up with teams from Bichat Hospital in Paris, one of the world leaders in Digestive Oncology. This large-scale experiment will allow us not only to obtain our Proof of Efficacy, but also to begin to test the feasibility for the Human Prototype, and to explore the response of other cancerous lineages (glioblastoma, hepatic adenocarcinoma).

In parallel, we are also working on the drafting of specifications for the realization of the human prototype. It should be noted that field gradient generator prototypes for humans have already been developed and tested in MPI (Magnetic Particle Imagery), in particular by Philips and Bruker. That is reassuring news about the technical feasibility and toxicity of our device.

governance

Founded in 2009 by members of the Brossel family, CC & C is a Société Anonyme (SA) with a capital of 395.075 € with 87 shareholders (march 2018). The patent belongs to the company.

The team

Barthélémy Brossel
CEO

In charge of administration and communication.

Rémy Brossel
CSO

Medical oncologist and physicist, he ensures the interface between the various scientific partners, subcontractors and opinion leaders.

Christine Grau
Executive Assistant

The Scientific Council

Daniel Gabay
Mathematician (Polytechnique, PhD)

Retired Director of Research in Mathematics at CNRS

Stéphane David
Industrial Manager (PhD, CEA)
Specialist in electro-magnetism

Christian Chillet
Researcher (PhD, CNRS / G2E Lab)

Specialist in electro-magnetism

Jean-Marc Guinebretière
MD (Institut Curie)

Pathologist

Eric Peltier
MD, CEO of Novacyt

Specialist in the development of medical devices

Roy Wiener
Medical Oncologist (Retired Dean Ass, Tulane Uni., US-LA)

A bridge to American healthcare institutions

partners

Adapted and flexible ecosystem

We have chosen to work in a network to add, on a case by case basis and according to needs, the skills we need.

For electro-technical engineering :

For research and experimentation :

Institutional partners :

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles